Serum Uric Acid and Non-Alcoholic Fatty Liver Disease in Non-Diabetic Chinese Men

Yuanliang Xie¹, Mengjie Wang², Youjie Zhang¹, Shijun Zhang², Aihua Tan², Yong Gao², Zhengjia Liang³, Deyi Shi³, Zhang Huang³, Haiyong Zhang⁴, Xiaoobo Yang⁴, Zheng Lu¹, Chunlei Wu¹, Ming Liao¹, Yu Sun¹, Xue Qin¹, Yanling Hu¹, Li Li², Tao Peng³, Zhixian Li⁵, Xiaoli Yang⁶*, Zengnan Mo¹²

¹ Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China, 2 Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China, 3 Medical Examination Center, Fangchenggang First People’s Hospital, Fangchenggang, Guangxi Zhuang Autonomous Region, China, 4 Department of Occupational Health and Environmental Health at School of Public Health, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China, 5 Department of Ultrasound, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China, 6 Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China, 7 Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China, 8 Department of Hepatobiliary Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

Abstract

Increased serum uric acid (SUA) levels may be involved in the development of non-alcoholic fatty liver disease (NAFLD) in men presenting with metabolic syndrome (MetS) and/or insulin resistance. We aimed to determine the independent relationship between SUA and NAFLD in non-diabetic Chinese male population, and to explore the determinants of SUA levels among indexes of adiposity, lipid, and genotypes pertaining to triglycerides metabolism, inflammation, oxidative stress, and SUA concentrations. A total of 1440 men, classified depending on the presence of ultrasonographically detected NAFLD, underwent a complete healthy checkup program. Genotypes were extracted from our previously established genome-wide association study database. After adjusting for age, smoking, drinking, body mass index, homeostasis model assessment of insulin resistance, C-reactive protein, creatinine, alanine aminotransferase (ALT) and components of metabolic syndrome, the odds ratio for NAFLD, comparing the highest with the lowest SUA quartile, was 2.81 (95% confidence interval 1.66–4.76). A stepwise multivariate linear regression analysis (R² = 0.238, P<0.001) retained age, waist circumference, serum creatinine, triglycerides, the Q141K variant in ABCC2 and NAFLD as significant predictors of SUA levels (all P<0.001). Besides, ALT and Met196Arg variant in TNFRSF1B were associated with SUA among individuals with NAFLD. Our data suggest that in Chinese men, elevated SUA is significantly associated with NAFLD, independent of insulin resistance and other metabolic disorders, such as central obesity or hypertriglyceridemia. Meanwhile, among subjects with NAFLD, index of liver damage, such as elevated ALT combined with genetic susceptibility to inflammation associated with increased SUA levels.

Introduction

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of pathologic conditions including simple steatosis, nonalcoholic steatohepatitis and cirrhosis, influences approximately 20–30% of the general population and its prevalence is increasing worldwide [1]. In China, with continually increasing pandemic of metabolic disorders, such as obesity, insulin resistant and metabolic syndrome (MetS) [2], NAFLD has also been emerging at an alarming rate and posing a very large proportion of the Chinese population at risk of impending liver diseases in the next decade [3,4]. NAFLD is commonly associated with obesity and insulin resistance, which per se are closely related to a cluster of other metabolic abnormalities, such as hypertriglyceridemia and hyperuricemia [5].

Recently, mounting evidence suggests that elevated serum uric acid (SUA) frequently associates with the development or progression of NAFLD [6,7]. Several evidences linking SUA and NAFLD have been provided from large population based study of Chinese and American people [8,9]. Li et al found that SUA level was significantly associated with NAFLD, independ of age, body mass index (BMI), blood lipids, and fasting plasma glucose [8]. While another study suggested that elevated SUA level associated with the development of cirrhosis and increased serum liver enzymes [9]. Prior epidemiological studies showed that UA is an independent risk factor for cardiovascular diseases [10,11], and the
pathological processes included insulin resistance, oxidative stress, and systemic inflammation [12,13], which are all considered as important risk factors for the development or progression of NAFLD [14]. In fact, a recent cross-sectional analysis of 10732 adults who participated in the National Health and Nutrition Examination Survey 1988–1994 also demonstrated that elevated uric acid level is independently associated with ultrasound-diagnosed NAFLD, regardless of insulin resistance, components of MetS, and indexes of liver and kidney function [15].

Serum uric acid, balanced between serum uric acid production and excretion, is the end product of purine metabolism by liver [16]. Hyperuricemia is a common finding in patients with metabolic syndrome or its components, such as central obesity and hypertriglyceridemia [17]. An inverse correlation was also noted between insulin resistance and decreased renal uric acid clearance, which is itself associated with elevated SUA [18]. In addition, increased triglycerides synthesis in individuals with metabolic abnormalities would also accelerate SUA production and accumulation [5]. Besides, inflammatory factors, such as tumor necrosis factor α and it induced oxidative and apoptosis stress have been suggested to be important factors for more serious liver damage, resulting in uric acid production. Since raising evidences suggest that chronic elevation of SUA concentration would be a causal factor for diseases, such as metabolic abnormalities and cardiovascular mortality, a well understanding of factors that influence SUA levels in population or in NAFLD patients will provide a more accurate interpretation of SUA-NAFLD relationship and has potential implications on NAFLD treatment in the population. Therefore, the purpose of the present study is 2-fold: (1) to test the hypothesis that SUA-NAFLD interrelationship occurs independently from insulin resistance, MetS, and its components; (2) to explore the determinants of SUA levels among indexes of adiposity, lipid, and genotypes pertaining to triglycerides metabolism, inflammation, oxidative stress, and SUA concentrations in a large series of non-diabetic Chinese men.

Participants and Methods

Study Population

All subjects, who participated in a large-scale physical examination from September 2009 to December 2009, were recruited continuously from the Fangchenggang Area Male Healthy and Examination Survey (FAMHES). The study has been described previously in detail [19]. In brief, FAMHES is a population-based epidemiological cohort study in area of Guangxi, China, aiming at investigating the effects of environmental and genetic factors and their interaction on the health of male and the progress of age-related chronic diseases. After excluded subjects who currently diagnosed with diabetes mellitus, coronary heart disease, stroke, hyperthyroidism, rheumatoid arthritis, and cancer or taking any kind of medication within four weeks, or with impaired hepatic and renal function, 2426 subjects aged 20–69 years were included. Of those eligible, subjects with incomplete data involved ultrasonography (n = 212), blood test values (n = 342), and genotype of the whole genome (n = 83), or with hepatitis B infection (n = 268), alcohol consumption >40 g/day and >5 times/week (n = 52), or C-reactive protein (CRP) value higher than 10 mg/L (n = 29) were further excluded to avoid bias. Finally, 1440 men with complete data were included for analyses. All subjects provided written informed consents, and the study was approved by Ethics and Human Subject Committee of Guangxi Medical University.

Data Collection

Participants in the FAMHES underwent a detailed medical interview that included information on demographics, medical history, smoking status and alcohol consumption. Current smokers were defined as smoking at least once a day and lasting for more than six months. Alcohol consumption was defined as consumption of alcoholic drinks (beer, wine, or hard liquor) once or more per week. Anthropometric parameters, including height, weight, waist circumference (WC), and blood pressure were measured by trained personnel using a standardized protocol [20]. BMI was calculated as weight in kilograms divided by the square of height in meters. Fasting blood samples were drawn between 8 a.m. and 10 a.m. Serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, fasting blood glucose (FBG), alanine aminotransferase (ALT), serum creatinine and SUA were measured using a Dimension-RxL Chemistry Analyzer (Dade Behring, Newark, DE, USA). Insulin was measured using COBAS 6000 system E601 electrochemiluminescence immunoassay (Roche Diagnostics, IN, Germany), and high-sensitivity CRP level was detected using the immunoturbidimetric assay on the Hitachi 7600 autoanalyzer (Hitachi Corp, Tokyo, Japan).

Ultrasoundography

Two experienced ultrasonographers assessed for liver size, contour, echogenicity, structure and posterior beam attenuation. Fatty liver was diagnosed based on the findings of abdominal ultrasonography using a portable ultrasound device (GE, LOGIQ e, 5.0-MHz transducer, USA) and included the presence of increased liver echogenicity (bright), and stronger echoes in the hepatic parenchyma than in the renal parenchyma, vessel blurring and narrowing of the lumen of the hepatic veins [21,22].

Definition of disease

The diagnosis of NAFLD was based on abdominal ultrasound without including alcohol consumption, viral, or autoimmune liver disease [23]. Men with a SUA level >420 μmol/L was defined as hyperuricemia [24]. Insulin resistance was assessed through the homeostasis model assessment algorithm using the following established formulas: glucose (mmol/liter)×Insulin (mU/liter)/22.5, and a value of 2.4 or higher was considered insulin resistant [25]. The metabolic syndrome was diagnosed using the 2005 National Cholesterol Education Program-Adult Treatment Panel III [NCEP-ATP III] criteria for Asian Americans [26]. The NCEP-ATP III has defined the metabolic syndrome as the presence of three or more of the five characteristics of (1) waist circumference ≥90 cm; (2) triglycerides ≥1.7 mmol/L, (3) HDL-C ≤1.93 mmol/L, (4) blood pressure ≥130/85 mm Hg or current use of antihypertensive medications, and (5) fasting blood glucose ≥5.6 mmol/L or previous diagnosis of type 2 diabetes mellitus or use of oral antidiabetic agents or insulin.

DNA analysis

We extracted several polymorphisms related to lipid metabolism (rs738409 in PNPLA3) [27], inflammation (rs1800629 in TNFz, rs1061622 in TNFRSF1B, and rs1892284 in IL6Rz) and oxidative stress (rs807829 in UGT1A1 and rs4880 in SOD2) that had been previously found to be associated with metabolic disorders such as obesity and NAFLD [28,29,30], and variants involved in uric acid concentrations (rs2231142 in ABCG2, rs1165205 in SLC17A3, missense rs16890979 in SLC2A9) [31,32], in our previously established genome-wide association database [19]. The genotyping methods have been described previously [19].
Table 1. Characteristics of participants according to quartile (Q) of serum uric acid (n = 1440).

| Variable                        | Serum uric acid quartile |       |       |       |       |       |       |
|---------------------------------|--------------------------|-------|-------|-------|-------|-------|-------|
|                                 | Q1 (n = 360)             | Q2 (n = 363) | Q3 (n = 366) | Q4 (n = 351) |       |       |
| Uric acid (µmol/L)              | 288.3 ± 1.8              | 350.6 ± 0.7 | 400.2 ± 0.8 | 490.4 ± 3.0 | <0.001 |       |
| Age (years)                     | 38.8 ± 0.6               | 37.2 ± 0.6 | 37.0 ± 0.6 | 37.5 ± 0.6 | 0.113  |       |
| Current smoker (n, %)           | 177 (49.2)               | 184 (50.7) | 186 (50.8) | 170 (48.4) | 0.899  |       |
| Alcohol drinker (n, %)          | 297 (82.5)               | 312 (86.0) | 317 (86.6) | 305 (86.9) | 0.31   |       |
| NAFLD (n, %)                    | 36 (10.0)                | 71 (19.6) | 120 (32.8) | 152 (43.3) | <0.001 |       |
| BMI (kg/m²)                     | 22.2 ± 0.1               | 22.9 ± 0.2 | 23.6 ± 0.2 | 24.9 ± 0.2 | <0.001 |       |
| Waist circumference (cm)        | 77.7 ± 0.4               | 79.5 ± 0.5 | 81.5 ± 0.5 | 85.3 ± 0.5 | <0.001 |       |
| Systolic blood pressure (mmHg)  | 117.6 ± 0.8              | 117.0 ± 0.7 | 118.3 ± 0.8 | 121.0 ± 0.8 | 0.003  |       |
| Diastolic blood pressure (mmHg) | 75.7 ± 0.5               | 75.6 ± 0.5 | 77.7 ± 0.5 | 79.5 ± 0.6 | <0.001 |       |
| LDL-C (mmol/L)                  | 2.87 ± 0.04              | 2.97 ± 0.04 | 3.00 ± 0.04 | 3.15 ± 0.04 | <0.001 |       |
| HDL-C (mmol/L)                  | 1.44 ± 0.02              | 1.41 ± 0.02 | 1.36 ± 0.02 | 1.33 ± 0.02 | <0.001 |       |
| Triglycerides (mmol/L)          | 1.27 ± 0.08              | 1.45 ± 0.10 | 1.61 ± 0.09 | 2.04 ± 0.09 | <0.001 |       |
| Glucose (mmol/L)                | 5.36 ± 0.06              | 5.27 ± 0.05 | 5.29 ± 0.05 | 5.33 ± 0.03 | 0.589  |       |
| Metabolic syndrome (n, %)       | 25 (6.9)                 | 35 (9.6)  | 52 (14.2)  | 90 (25.6)   | <0.001 |       |
| Insulin (mU/L)                  | 6.6 ± 0.3                | 7.2 ± 0.3  | 8.1 ± 0.3  | 10.4 ± 0.5  | <0.001 |       |
| HOMA-IR                         | 1.6 ± 0.1                | 1.7 ± 0.1  | 1.9 ± 0.1  | 2.5 ± 0.1   | <0.001 |       |
| C-reactive protein (mg/L)       | 0.93 ± 0.08              | 0.96 ± 0.07 | 1.03 ± 0.07 | 1.15 ± 0.07 | 0.152  |       |
| ALT (IU/L)                      | 39.4 ± 1.03              | 42.0 ± 1.07 | 47.9 ± 1.44 | 53.2 ± 1.55 | <0.001 |       |
| Creatinine (µmol/L)             | 82.2 ± 0.6               | 85.4 ± 0.6 | 89.2 ± 0.6 | 92.7 ± 0.7  | <0.001 |       |

Data are means ± SE or raw numbers (%). Continuous data were used for univariate general linear models and categorical data were analyzed by χ² tests. Abbreviation: ALT, alanine aminotransferase; BMI, body mass index; LDL-C, serum low-density lipoprotein cholesterol; HDL-C, serum high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; NAFLD, nonalcoholic fatty liver disease.

doi:10.1371/journal.pone.0067152.t001

Statistical Analysis

We classified participants on the basis of quartiles of serum uric acid, with data presented as mean ± SE. For descriptive analyses across the quartile group of SUA, we performed chi-square analyses for categorical variables and ANOVA for continuous traits. Logistic regression analyses were used to assess the association of NAFLD, MetS or its components with SUA, and results were presented by odds ratio (OR) and 95% confidence intervals (CI). A multivariate linear regression analysis was used to determine the effects of anthropometric, clinical, metabolic, and genetic variants on the logarithm of SUA concentrations. For maintaining the symmetry and comparability of per-unit-effect estimates, all models presented use log-transformed values of blood variables. All statistical analyses were performed with PASW Statistics 18 (Chicago, IL, USA). Statistical tests were 2-sided, and a P value <0.05 was considered statistically significant.

Association between Serum Uric Acid Concentrations and NAFLD, MetS or its Components

The ORs for NAFLD increased progressively across the SUA quartiles (all P<0.001 for trend) (Table 2). After adjusting for age, smoking, and drinking (model 1), the OR for NAFLD, comparing the highest with the lowest SUA quartile, was 7.51 (95% CI 4.98–11.31). Further adjustment for BMI (model 2) substantially attenuated the magnitude of the ORs for NAFLD, but did not affect statistical significance. Using the lowest SUA quartile as reference, the ORs for NAFLD was 1.95 (95% CI 1.16–3.31), 3.08 (95% CI 1.85–5.14), and 2.81 (95% CI 1.66–4.76) for quartiles 2, 3, and 4, respectively (P<0.001 for trend), after further adjusting for HOMA-IR, CRP, creatinine, ALT and components of metabolic syndrome (model 5).

The ORs for metabolic syndrome substantially increased with increasing concentrations of SUA (Table 2). Compared with individuals in the lowest SUA quartile, those in the highest quartile had an OR of 1.98 (95% CI 1.12–3.50) in the full multivariate model (model 4). Further adjusted for components of MetS (without component itself), SUA was positively associated with hypertriglyceridemia (OR = 3.11, 95% CI 2.03–4.77) (P<0.001 for trend), and central obesity (OR = 2.01, 95% CI 1.00–4.03) with a borderline statistical significance (P = 0.05).

We also duplicated our analysis among subgroups with or without MetS, central obesity, or hypertriglyceridemia (Figure 1). In general, the risks of NAFLD were more pronounced among subjects with higher concentration of SUA and with combination

Results

Patient Characteristics

Among the 1440 participants, the median age of the study was 36 years (interquartile range, 29–44), and median SUA was 374.0 µmol/L (interquartile range, 326.3–426.0). The prevalence of hyperuricemia, NAFLD and MetS were 27.6% (n = 398), 26.3% (n = 379) and 14.0% (n = 202), respectively. Table 1 shows the characteristics of study subjects according to quartile of SUA. Participants with higher serum uric acid concentrations exhibited higher prevalence of NAFLD and MetS. Meanwhile, BMI, waist circumference, systolic and diastolic blood pressure, LDL-C, triglycerides, fasting insulin, HOMA-IR, ALT, and serum creatinine were significantly higher, while HDL-C was lower, among men with higher SUA levels.
Factors Associated With Serum Uric Acid Concentrations

Ln-normalized SUA level was introduced as a dependent variable in the multivariate linear regression models (Figure 2), using age, BMI, waist circumference, NAFLD and MetS (both classified as yes or no), and log-transformed values of triglycerides, CRP, HOMA-IR, creatinine, and ALT, and the genomic variants as independent variable. Overall, this model explained 23.5% of the variability in logarithm of SUA concentrations. Among all subjects, a final constructed model using a stepwise method (probability to enter ≤0.05; to remove ≥0.10), found age (β = −0.11, 95% CI −0.16 to −0.06), WC (β = 0.17, 95% CI 0.11–0.23), NAFLD (β = 0.15, 95% CI 0.09–0.21), log-transformed serum creatinine (β = 0.29, 95% CI 0.24–0.34) and triglycerides (β = 0.11, 95% CI 0.05–0.16), as well as the Q141K variant in ABCG2 gene (β = 0.12, 95% CI 0.07–0.17) as significant predictors (all P<0.001) of the logarithm of SUA levels (R² = 0.238, P<0.001). When duplicated our stepwise regression analysis among subjects with NAFLD, interestingly, the WC (β = 0.21, 95% CI 0.09–0.33, P = 0.001), log-transformed triglycerides (β = 0.11, 95% CI 0.02–0.20, P = 0.02), creatinine (β = 0.19, 95% CI 0.10–0.28, P<0.001), and ALT (β = 0.14, 95% CI 0.05–0.24, P = 0.003), and the Met196Arg variant in TNFRSF1B gene (β = 0.10, 95% CI 0.01–0.20, P = 0.027) were positively associated with logarithm of SUA concentrations (R² = 0.148, P<0.001).

Table 2. Odds ratios and 95% confidence interval for NAFLD, metabolic syndrome, and its components according to quartile (Q) of serum uric acid.

| Serum uric acid | Q1     | Q2     | Q3     | Q4     | P for trend |
|---|---|---|---|---|---|
| NAFLD | 1.00 | 2.34 (1.51–3.61) | 4.79 (3.17–7.24) | 7.51 (4.98–11.31) | <0.001 |
| Metabolic syndrome | 1.00 | 1.84 (1.13–3.02) | 3.17 (1.99–5.07) | 3.35 (2.10–5.34) | <0.001 |
| Components of metabolic syndrome* | | | | | |
| Central obesity | 1.00 | 1.05 (0.58–1.92) | 1.32 (0.75–2.31) | 2.01 (1.17–3.44) | 0.019 |
| Elevated BP | 1.00 | 1.05 (0.58–1.92) | 1.32 (0.75–2.31) | 2.01 (1.17–3.44) | 0.019 |
| Low HDL cholesterol | 1.00 | 1.06 (0.58–1.94) | 1.31 (0.74–2.30) | 2.10 (1.22–3.63) | 0.012 |
| Hyperglycemia | 1.00 | 1.03 (0.56–1.89) | 1.26 (0.71–2.25) | 1.98 (1.12–3.50) | 0.031 |

Model 1 was adjusted for age smoking, and drinking; Model 2 was further adjusted for BMI; Model 3 was further adjusted for HOMA-IR and C-reactive protein; Model 4 was further adjusted for serum creatinine and alanine aminotransferase; Model 5 was further adjusted for the components of metabolic syndrome (variables as categories). *Fully adjusted model without component itself. Serum levels of HOMA-IR, C-reactive protein, creatinine and alanine aminotransferase were log transformed.

Discussion

We observed a strong positive association between elevated serum uric acid levels and the risks of NAFLD in non-diabetic Chinese men, independent of insulin resistance or metabolic syndrome status. Our data implied the crucial role of SUA as an important independent risk factor for NAFLD. In addition, we identified a missense SNP in ABCG2 gene (rs2231142) associated with SUA level, further clustered with independent variables, such as age, waist circumference, NAFLD, creatinine and triglycerides, which explained 23.8% of the variability in the logarithm of serum uric acid concentration. Besides, ALT and variant Met196Arg of TNFRSF1B gene (rs1061622) combined with WC, creatinine, and triglycerides, associated with SUA among subjects with NAFLD.

Uric Acid and Non-Alcoholic Fatty Liver Disease

Abbreviation: BP, blood pressure; NAFLD, nonalcoholic fatty liver disease.

doi:10.1371/journal.pone.0067152.t002
Studies have consistently shown an association between elevated uric acid (UA) levels and non-alcoholic fatty liver disease (NAFLD). This suggests that UA might be an important contributor to the development of NAFLD. In studies of 8925 employees of Ningbo province in China, hyperuricemia was related to NAFLD, independently of metabolic risk factors at baseline, and after a 3-year follow-up, UA levels were independently and positively associated with the risk for incident NAFLD, although insulin resistance was not considered [6,8]. Another prospective study among healthy Korean men also found SUA appeared to be an independent predictor for developing ultrasonographically detected NAFLD; the investigators did not measure the waist circumference, which may be a better surrogate marker of central obesity [7]. Our data combined with previous findings suggested that higher levels of SUA are commonly associated with metabolic syndrome and its five components, especially central obesity and hypertriglyceridemia [17], which are tightly related to NAFLD [34]. In addition, we also noted a strong positive association between higher levels of SUA and the risks of NAFLD, independent of index of obesity, insulin resistance, MetS, and liver and kidney function. Although SUA increase is also observed in individuals with insulin resistance, we found that the increased risks for NAFLD by hyperuricemia could not be explained merely through peripheral HOMA-IR. The possible explanation is that SUA increase is individuals with insulin resistance, probably because hyperinsulinemia would cause lower renal UA excretion [35], and indirect act on SUA via reduction of adipocyte sensitivity to insulin and then increases triglyceride lipolysis within adipose depots [5].

Metabolic and renal factors and genetic variation might contribute to determining uric acid concentration through regulation of uric acid synthesis, excretion, or reabsorption [36]. Because whether SUA as a marker or a cause or both, strategies that aim at monitoring or decreasing SUA levels may have clinical beneficial effects to prevent or reduce the risk of NAFLD. Our present result also suggested that the Q141K variant in ABCG2, leads to variable degree of SUA concentration in men, in conceptual agreement with the ABCG2's function of altering uric acid transport in kidney proximal tubule cell and excretion in liver via the biliary system [37]. However, more importantly, the relatively strong association of increased SUA levels with NAFLD raises the possibility that SUA overload might play some pathogenic role in the development of NAFLD, given that progressive SUA accumulation contributes to inflammatory and oxidative effects [12,13]. On the contrary, these levels are not influenced by global obesity, MetS, CRP, HOMA-IR, ALT or by genomic variants related to PNPLA3, chronic inflammation, and oxidative stress in the overall population.

Recently, evidence revealed that uric acid, released from injured cells, induced sterile inflammation [38,39]. Small molecules like ATP or large crystals like UA can be transformed or exported from the liver under normal physiological condition. However, non-alcoholic steatohepatitis, one of important component of liver damage, might induce cell death results in the release and accumulation of molecules are not present in the extracellular environment during health, such as UA [40]. Thus, our results of positive association of elevated serum ALT and the Met196Arg variant in TNFRSF1B with SUA concentrations among subjects with NAFLD further support this proposal, which is called damage associated molecular patterns (DAMPS), and suggested that the release of UA might be accelerated when tissue injury (combined with a genetic susceptibility to inflammation) happened in NAFLD patients [41]. Then UA as a promising production of DAMPs triggers sterile inflammation and increases organ damage, based on prior hypothesis role of inducing inflammation and oxidative stress.

Figure 1. Odds ratios (OR) and 95% confidence interval (CI) for NAFLD. Adjusted for age, smoking, drinking, BMI, HOMA-IR, C-reactive protein, creatinine and alanine aminotransferase The black and white circles are the ORs for NAFLD among subjects with or without MetS (A), central obesity (B), and hypertriglyceridemia (C) respectively. The error bars indicate the 95% CI of OR, and broken lines indicate the OR = 1. Serum levels of HOMA-IR, C-reactive protein, creatinine and alanine aminotransferase were log transformed.

doi:10.1371/journal.pone.0067152.g001

Our findings are partly consistent with and extend an earlier Chinese cross-sectional study [8], which reported lower prevalence of hyperuricemia (14.7% vs. 27.6%) and NAFLD (11.8% vs. 26.3%) than our results. A possible explanation for the different prevalence may originate from the characteristics of the studied populations. In the present study, Fangchenggang people living in coastal areas have a relatively frequent seafood diet, which are closely related with elevated serum uric acid [33], and possibly influence the natural characteristics of NAFLD.

Studies have consistently shown an association between elevated SUA and risk of NAFLD, and are in accord with prior hypotheses suggesting that SUA might be an important contributor to the development of NAFLD. In studies of 8925 employees of Ningbo province in China, hyperuricemia was related to NAFLD, independently of metabolic risk factors at baseline, and after a 3-year follow-up, SUA levels were independently and positively associated with the risk for incident NAFLD, although insulin resistance was not considered [6,8]. Another prospective study among healthy Korean men also found SUA appeared to be an independent predictor for developing ultrasonographically detected NAFLD; the investigators did not measure the waist circumference, which may be a better surrogate marker of central obesity [7]. Our data combined with previous findings suggested that higher levels of SUA are commonly associated with metabolic syndrome and its five components, especially central obesity and hypertriglyceridemia [17], which are tightly related to NAFLD [34]. In addition, we also noted a strong positive association between higher levels of SUA and the risks of NAFLD, independent of index of obesity, insulin resistance, MetS, and liver and kidney function. Although SUA increase is also observed in individuals with insulin resistance, we found that the increased risks for NAFLD by hyperuricemia could not be explained merely through peripheral HOMA-IR. The possible explanation is that SUA increase is individuals with insulin resistance, probably because hyperinsulinemia would cause lower renal UA excretion [35], and indirect act on SUA via reduction of adipocyte sensitivity to insulin and then increases triglyceride lipolysis within adipose depots [5].

Metabolic and renal factors and genetic variation might contribute to determining uric acid concentration through regulation of uric acid synthesis, excretion, or reabsorption [36]. Because whether SUA as a marker or a cause or both, strategies that aim at monitoring or decreasing SUA levels may have clinical beneficial effects to prevent or reduce the risk of NAFLD. Our present result also suggested that the Q141K variant in ABCG2, leads to variable degree of SUA concentration in men, in conceptual agreement with the ABCG2's function of altering uric acid transport in kidney proximal tubule cell and excretion in liver via the biliary system [37]. However, more importantly, the relatively strong association of increased SUA levels with NAFLD raises the possibility that SUA overload might play some pathogenic role in the development of NAFLD, given that progressive SUA accumulation contributes to inflammatory and oxidative effects [12,13]. On the contrary, these levels are not influenced by global obesity, MetS, CRP, HOMA-IR, ALT or by genomic variants related to PNPLA3, chronic inflammation, and oxidative stress in the overall population.

Recently, evidence revealed that uric acid, released from injured cells, induced sterile inflammation [38,39]. Small molecules like ATP or large crystals like UA can be transformed or exported from the liver under normal physiological condition. However, non-alcoholic steatohepatitis, one of important component of liver damage, might induce cell death results in the release and accumulation of molecules are not present in the extracellular environment during health, such as UA [40]. Thus, our results of positive association of elevated serum ALT and the Met196Arg variant in TNFRSF1B with SUA concentrations among subjects with NAFLD further support this proposal, which is called damage associated molecular patterns (DAMPS), and suggested that the release of UA might be accelerated when tissue injury (combined with a genetic susceptibility to inflammation) happened in NAFLD patients [41]. Then UA as a promising production of DAMPs triggers sterile inflammation and increases organ damage, based on prior hypothesis role of inducing inflammation and oxidative stress.

Figure 1. Odds ratios (OR) and 95% confidence interval (CI) for NAFLD. Adjusted for age, smoking, drinking, BMI, HOMA-IR, C-reactive protein, creatinine and alanine aminotransferase The black and white circles are the ORs for NAFLD among subjects with or without MetS (A), central obesity (B), and hypertriglyceridemia (C) respectively. The error bars indicate the 95% CI of OR, and broken lines indicate the OR = 1. Serum levels of HOMA-IR, C-reactive protein, creatinine and alanine aminotransferase were log transformed.

doi:10.1371/journal.pone.0067152.g001
We simultaneously investigate the effects of metabolic syndrome and its components, and insulin resistance on the relationship between SUA and NAFLD in a large population-based sample. And to our knowledge, we first explore the determinants of SUA levels among multiple variables and genotypes in Chinese men. However, several potential limitations are admitted. First, NAFLD diagnosis is based on ultrasound imaging, which is neither sensitive enough to distinguish hepatic steatosis from NASH, nor to distinguish the stage of hepatic fibrosis only in the case that cirrhosis is present. However, ultrasonographic examination currently remains the primary method for epidemiologic studies of NAFLD owing to its non-invasiveness, safety, wide availability and convenience. Second, given the nature of cross-sectional study, whether elevated SUA is a cause or an effect of NAFLD cannot be answered accurately. Furthermore, a recent study showed that hyperuricaemia was independently associated with severity of steatosis among chronic hepatitis C patients; therefore, another potential limitation might be including patients with

![Predictors of Serum Uric Acid](image)

Figure 2. Multiple linear regression analysis of the logarithm of serum uric acid. The squares are the standardized regression coefficients ($\beta$) and the error bars indicate the 95% CI of $\beta$, and broken lines indicate the $\beta$ coefficients = 0. Genomic variants were coded as dummy variables: 0 for homozygosity for wild-type alleles, 1 for heterozygosity, and 2 for homozygosity for effect alleles.

doi:10.1371/journal.pone.0067152.g002
hepatitis C virus infection, due to the absence of diagnostic markers in our study.

In conclusion, elevated serum uric acid is independently associated with NAFLD regardless of insulin resistance and metabolic syndrome status, especially hypertriglyceridemia or central obesity. SUA are independently associated with NAFLD, creatinine, triglycerides, and the Q141K variant in ABCG2 in non-diabetic Chinese men. Meanwhile, among subjects with NAFLD, index of liver damage, such as elevated ALT combined with genetic susceptibility to inflammation (Met196Arg variant in TNFRSF1B) associated with increased SUA levels. Strategies that aim at modulating the SUA levels and/or improving liver function may have significant clinical implications for the prevention and treatment of NAFLD.

Author Contributions
Conceived and designed the experiments: ZM. Performed the experiments: YX MW YZ Z. Lu CW ML,YS. Analyzed the data: Xiaoli Yang MW YH. Contributed reagents/materials/analysis tools: SZ ZH XQ AT YG. Wrote the paper: MW YJ. Coordinated the project: Z. Liang, DS HZ Xiaobo Yang LL TP Z. Li.

References
1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221–1231.
2. Guo JD, Reynolds K, Wu X, Chen J, Duan X, et al. (2005) Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365: 1380–1385.
3. Fan JG, Zhu J, Li XJ, Chen L, Li L, et al. (2005) Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 43: 509–514.
4. Hou XH, Zhu YX, Lu HJ, Chen HF, Li Q, et al. (2011) Non-alcoholic fatty liver disease’s prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. J Gastroenterol Hepatol 26: 722–730.
5. Choi SS, Diehl AM (2008) Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 19: 293–300.
6. Xu C, Yu C, Xu L, Miao M, Li Y (2010) High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS One 5: e11578.
7. Ryu S, Chang Y, Kim SG, Cho J, Guallar E (2011) Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism 60: 869–876.
8. Li Y, Xu C, Yu C, Xu L, Miao M (2009) Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 50: 1029–1034.
9. Azfall A, Weiss NS, Boyko EJ, Joannou GN (2010) Association between serum uric acid level and chronic liver disease in the United States. Hepatology 52: 578–589.
10. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359: 1011–1021.
11. Gaffo AL, Edwards NL, Saag KG (2009) Gout, Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther 11: 240.
12. Sautin YY, Nakagawa T, Zarhukov S, Johnson RJ (2007) Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293: C384–396.
13. Beavers KM, Beavers DP, Serra MC, Bowden RG, Wilson RL (2009) Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels findings from the NHANES III. J Nutr Health Aging 13: 177–182.
14. Powell EE, Johnson JR, Clouston AD (2010) Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis 28: 186–191.
15. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, et al. (2013) Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States. Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 62: 392–399.
16. Alvarez-Lario B, Macarron-Vicente J (2010) Uric acid and rheumatoid arthritis. Rheumatology (Oxford) 49: 2010–2015.
17. Ouattar A, Uyehara H, Hergue G, Kabaibout A, Albayakr S, et al. (2006) Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19: 1055–1062.
18. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, et al. (2005) Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69: 928–933.
19. Tan A, Sun J, Xia N, Qin X, Hu Y, et al. (2012) A genome-wide association and gene-environment interaction study for serum triglycerides levels in a healthy Chinese male population. Hum Mol Genet 21: 1655–1664.
20. Tian GX, Sun Y, Pang CJ, Tan AH, Gao Y, et al. (2012) Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev 13: 381–387.
21. Saadeh S, Youmossi ZM, Remer EM, Gramlich T, Ong JP, et al. (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 743–750.
22. Meziri M, Pereira WC, Abdelwahab A, Degott C, Laugier P (2005) In vitro chronic hepatic disease characterization with a multiparametric ultrasonic approach. Ultrasounds 13: 893–913.
23. Bedogni G, Miglioli L, Masotti F, Tinibelli C, Marchesini G, et al. (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44–52.
24. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 283: 2404–2410.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
26. Grundy SM, Clemens JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Circulation 112: 2272–2283.
27. Peng W, Xu WL, Lu SW, Lu QH, Hu ZJ, et al. (2012) Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. PLoS One 7: e50256.
28. Tokushima K, Takamasa K, Tsuchiya-Matsushita N, Tanai M, Hashimoto E, et al. (2007) Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 46: 1104–1110.
29. Lin YC, Chang PF, Hu FO, Chang MH, Ni YH (2009) Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics 124: e1221–e1227.
30. Al-Saari M, Anstee QM, Valenti L, Nohila V, Leathart JB, et al. (2012) The SOD2 C147T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 56: 448–454.
31. Delbagh A, Kottgen A, Yang Q, Hwang SJ, Kao WL, et al. (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372: 1593–1596.
32. Kolb M, Johnson T, Sanna S, Teumer A, Vitaat V, et al. (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5: e1000504.
33. Choi HK, Liu S, Curhan G (2005) Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. JAMA 294: 283–289.
34. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–923.
35. Faccini F, Chen YD, Hollenbeck CB, Reaven GM (1991) Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266: 3008–3011.
36. de Oliveira EP, Burini RC (2012) High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr 4: 12.
37. Kountouras J, Magoula I, Tasapas G, Lantis I (1996) The effect of maminol and secretin on the biliary transport of urate in humans. Hepatology 23: 229–233.
38. Petta S, Camma C, Caballia D, Di Marco V, Craci A (2011) Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 34: 757–766.
39. Cono H, Chen CJ, Omisiero F, Rock KL (2010) Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 120: 1391–1399.
40. Hoque R, Vodovozov Y, Medhal W (2013) Therapeutic strategies in inflamma-tome-related diseases of the liver. J Hepatol 50: 1047–1052.
41. Shi Y (2010) Caught red-handed: uric acid is an agent of inflammation. J Clin Invest 120: 1391–1399.